Patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy, a randomized trial showed.
A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer.
Patients with metastatic colorectal cancer who engaged in daily moderate physical activity demonstrated a reduction in mortality and cancer progression.
Activating, hotspot mutations in the NRAS gene occur in a small subset of patients with metastatic colorectal cancer. These mutations are now being identified in routine clinical practice by extended RAS genotyping.
It is highly probable that molecular profiling is the key to more precise treatments, as well as prediction of outcomes in metastatic colorectal cancer.
The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab for previously treated patients with advanced microsatellite instability-high cancer.
Alan P. Venook, MD, discusses key issues in metastatic colorectal cancer, including tumor sidedness and the conflicting data regarding the precise benefit of cetuximab in the frontline setting.
For a long time, patients with metastatic colorectal cancer had poor outcomes and very limited treatment options, said Tanios Bekaii-Saab, MD.
An overall survival analysis of 3 randomized controlled trials exploring Yttrium-90 (Y-90) resin microspheres may demonstrate noteworthy survival benefits for patients with liver-dominant metastatic colorectal cancer receiving first-line FOLFOX6 with or without bevacizumab plus Y-90 resin microspheres.
Mutation discordance between primary and metastatic sites in colorectal cancer may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.